BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.

BeiGene Ltd.

In a report released on December 9, Tony Ren from Macquarie maintained a Buy rating on BeiGene Ltd, with a price target of HK$236.00. The company’s...

Macquarie Sticks to Its Buy Rating for BeiGene Ltd (6160)

Onconetix ( ($ONCO) ) has shared an announcement. On December 6, 2025, Proteomedix AG, a subsidiary of Onconetix, Inc., amended its license agreeme...

Onconetix Amends License Agreement with Labcorp

An announcement from Oncolytics Biotech ( ($ONCY) ) is now available. Oncolytics Biotech Inc. has rescheduled its special meeting of shareholders t...

Oncolytics Biotech Plans Jurisdiction Shift to Nevada

The latest announcement is out from Onco-Innovations Ltd. ( ($TSE:ONCO) ). Onco-Innovations Limited, through its subsidiary Inka Health Corp., rece...

Onco-Innovations Leads Precision Oncology Forum to Shape Future Cancer Care

Onco-Innovations Ltd. ( ($TSE:ONCO) ) has provided an announcement. Onco-Innovations Limited has engaged a U.S. investment bank to advise on a pote...

Onco-Innovations Explores Nasdaq Cross-Listing and Equity Offering

RBC Capital analyst Piral Dadhania maintained a Hold rating on Moncler S.p.A. yesterday and set a price target of €56.00. Dadhania covers the Consu...

RBC Capital Sticks to Its Hold Rating for Moncler S.p.A. (0QII)

In a report released on December 1, from Daiwa maintained a Buy rating on BeiGene Ltd, with a price target of HK$240.00. The company’s shares close...

Daiwa Reaffirms Their Buy Rating on BeiGene Ltd (6160)

Oncolytics Biotech ( ($ONCY) ) has released its Q3 earnings. Here is a breakdown of the information Oncolytics Biotech presented to its investors. ...

Oncolytics Biotech Reports Q3 2025 Financial Results

An update from Onco-Innovations Ltd. ( ($TSE:ONCO) ) is now available. Onco-Innovations Limited attended the University of Alberta’s 2025 Innovatio...

Onco-Innovations Joins University of Alberta’s Innovation Awards, Advances Cancer Treatment Technology

In a report released today, Carole Madjo from Barclays maintained a Buy rating on Moncler S.p.A., with a price target of €61.00. According to TipRa...

Barclays Sticks to Its Buy Rating for Moncler S.p.A. (0QII)

Lake Street analyst Chad Messer maintained a Buy rating on Oncolytics Biotech today and set a price target of $7.00. Messer covers the Healthcare s...

Lake Street Sticks to Its Buy Rating for Oncolytics Biotech (ONCY)

RBC Capital analyst Douglas Miehm maintained a Buy rating on Oncolytics Biotech yesterday and set a price target of $3.50. According to TipRanks, M...

Oncolytics Biotech (ONCY) Gets a Buy from RBC Capital

Analysts fell to the sidelines weighing in on Avadel Pharmaceuticals (AVDL – Research Report) and Oncolytics Biotech (ONCY – Research Report) with ...

Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL) and Oncolytics Biotech (ONCY)

Onco-Innovations Ltd. ( ($TSE:ONCO) ) has provided an update. Onco-Innovations Limited has announced a collaboration with Kuano Ltd. to accelerate ...

Onco-Innovations Partners with Kuano to Enhance PNKP Inhibitor Development

RBC Capital analyst Leonid Timashev maintained a Buy rating on BeOne Medicines yesterday and set a price target of $408.00. The company’s shares cl...

RBC Capital Remains a Buy on BeOne Medicines (ONC)

Zymeworks ($ZYME) stock rallied 29% on Monday, after the clinical-stage biotechnology company announced positive Phase 3 trial results for its gast...

Zymeworks Stock (ZYME) Soars on Positive Results for Cancer Drug Ziihera, Top Analysts Boost Price Targets

The latest update is out from Oncolytics Biotech ( ($ONCY) ). Oncolytics Biotech Inc. has established a Gastrointestinal Tumor Scientific Advisory ...

Oncolytics Biotech Forms Advisory Board to Advance Pelareorep in GI Cancers

Saudi Arabia’s Public Investment Fund, known as the PIF, has further trimmed its holdings of many of its U.S. stock positions in the third quarter....

Saudi Public Investment Fund Sells Major U.S. Stocks as Portfolio Value Falls in Third Quarter

Loncor Gold ( ($TSE:LN) ) has issued an announcement. Loncor Gold Inc. has announced a special shareholders’ meeting to approve a proposed arrangem...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ONC	$319.06	-0.55%	179.67K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ONC	$319.06	-0.6%	179.67K
3
4
5
6

ONC

ONC

Get BeiGene Ltd. Data in Excel

Get BeiGene Ltd. Data in Excel